{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:19:26Z","timestamp":1793747966613,"version":"4.6.1"},"reference-count":178,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions characterized by extensive detachment of the epidermis and mucous membranes. These severe disorders carry a high mortality rate, and their pathogenesis remains largely unclear. Furthermore, optimal therapeutic strategies for SJS\/TEN remain a subject of ongoing debate. Early diagnosis of SJS\/TEN is challenging, and reliable biomarkers for diagnosis or severity prediction have not been firmly established. Certain drugs, such as carbamazepine and allopurinol, have shown a strong association with specific human leukocyte antigen (HLA) types. Recently, the potential benefits of HLA screening prior to administering these drugs to reduce the incidence of SJS\/TEN have been explored. Epidermal cell death in SJS\/TEN lesions is caused by extensive apoptosis, primarily through the Fas\u2013Fas ligand (FasL) and perforin\/granzyme pathways. Our findings suggest that necroptosis, a form of programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, interacts with the formyl peptide receptor 1 to induce necroptosis. Several biomarkers, such as CC chemokine ligand (CCL)-27, interleukin-15, galectin-7, receptor-interacting protein kinases 3 (RIP3), and lipocalin-2, have been identified for diagnostic and prognostic purposes in SJS\/TEN. Supportive care is recommended for treating SJS\/TEN, but the efficacy of various therapeutic options\u2013including systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and tumor necrosis factor-\u03b1 antagonists\u2013remains controversial. Recent studies have investigated the potential benefits of tumor necrosis factor-\u03b1 antagonists. In this review, we discuss recent advances in the understanding and management of SJS\/TEN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003250","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T04:00:27Z","timestamp":1725595227000},"page":"2294-2307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management"],"prefix":"10.1097","volume":"137","author":[{"given":"Akito","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"F1000FacultyRev\u2013612","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdermsci.2020.09.009","article-title":"The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018","volume":"100","author":"Sunaga","year":"2020","journal-title":"J Dermatol Sci"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1016\/j.jaip.2023.07.001","article-title":"Development and validation of a novel score to predict mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis: CRISTEN","volume":"11","author":"Hama","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.16398","article-title":"Cutaneous adverse drug eruption: The role of drug patch testing","volume":"62","author":"Thaiwat","year":"2023","journal-title":"Int J Dermatol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ced.12239","article-title":"Utility of patch testing for patients with drug eruption","volume":"39","author":"Ohtoshi","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.anai.2022.06.014","article-title":"Lymphocyte transformation test for drug allergy detection: When does it work?","volume":"129","author":"Gl\u00e4ssner","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: Dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"113062","DOI":"10.1016\/j.jim.2021.113062","article-title":"ELISpot assay as a diagnostic tool in drug hypersensitivity reactions","volume":"495","author":"Porebski","year":"2021","journal-title":"J Immunol Methods"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: A marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"R23-20250602","first-page":"290","article-title":"Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients","volume":"29","author":"Then","year":"2011","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"2011","journal-title":"Seizure"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FPC.0000000000000287","article-title":"HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population","volume":"27","author":"Khor","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/tan.12970","article-title":"A study of HLA-B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS\/TEN","volume":"89","author":"Ou","year":"2017","journal-title":"HLA"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/cts.13291","article-title":"Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis","volume":"15","author":"Biswas","year":"2022","journal-title":"Clin Transl Sci"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"R33-20250602","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","article-title":"HLA allele frequencies in 5802 Koreans: Varied allele types associated with SJS\/TEN according to culprit drugs","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","article-title":"Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population","volume":"115","author":"Ram\u00edrez","year":"2017","journal-title":"Pharmacol Res"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: An international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jid.2023.09.282","article-title":"Differential effects of HLA-B*15:11 and HLA-A*31:01 on carbamazepine-induced cutaneous adverse reactions","volume":"144","author":"Fukunaga","year":"2024","journal-title":"J Invest Dermatol"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell PB","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol"},{"key":"R48-20250602","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2013.04.013","article-title":"HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population","volume":"71","author":"Niihara","year":"2013","journal-title":"J Dermatol Sci"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.13688","article-title":"HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: A multicentre retrospective case-control clinical study","volume":"173","author":"Cheng","year":"2015","journal-title":"Br J Dermatol"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"R54-20250602","doi-asserted-by":"crossref","first-page":"81870","DOI":"10.18632\/oncotarget.13250","article-title":"Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: Evidence from 21 pharmacogenetic studies","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"R55-20250602","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: An updated systematic review and meta-analysis","volume":"20","author":"Yu","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R56-20250602","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J Rheumatol"},{"key":"R57-20250602","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R58-20250602","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"R59-20250602","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"R60-20250602","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R61-20250602","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R62-20250602","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R63-20250602","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R64-20250602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(\u00ae) observational database: A cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R65-20250602","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R66-20250602","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/bjophthalmol-2020-317315","article-title":"Association of HLA polymorphisms and acetaminophen-related Steven-Johnson syndrome with severe ocular complications in Thai population","volume":"106","author":"Jongkhajornpong","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R67-20250602","doi-asserted-by":"crossref","first-page":"649661","DOI":"10.3389\/fmed.2021.649661","article-title":"Findings by an international collaboration on SJS\/TEN with severe ocular complications","volume":"8","author":"Ueta","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R68-20250602","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41439-019-0082-6","article-title":"Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals","volume":"6","author":"Ueta","year":"2019","journal-title":"Hum Genome Var"},{"key":"R69-20250602","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R70-20250602","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"R71-20250602","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1346-8138.12674","article-title":"Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Abe","year":"2015","journal-title":"J Dermatol"},{"key":"R72-20250602","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1523-1747.1998.00122.x","article-title":"Molecular features of penicillin allergy","volume":"110","author":"Weltzien","year":"1998","journal-title":"J Invest Dermatol"},{"key":"R73-20250602","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0702453","article-title":"Cellular disposition of sulphamethoxazole and its metabolites: Implications for hypersensitivity","volume":"126","author":"Naisbitt","year":"1999","journal-title":"Br J Pharmacol"},{"key":"R74-20250602","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2222.2003.01718.x","article-title":"Mechanisms in cutaneous drug hypersensitivity reactions","volume":"33","author":"Friedmann","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"R75-20250602","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/tx900034r","article-title":"Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: Implications for hapten formation","volume":"22","author":"Callan","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"R76-20250602","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R77-20250602","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"R78-20250602","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2332\/allergolint.55.17","article-title":"Pharmacological interaction of drugs with immune receptors: The p-i concept","volume":"55","author":"Pichler","year":"2006","journal-title":"Allergol Int"},{"key":"R79-20250602","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"R80-20250602","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"R81-20250602","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"R82-20250602","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R83-20250602","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R84-20250602","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R85-20250602","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R86-20250602","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat Commun"},{"key":"R87-20250602","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"R88-20250602","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R89-20250602","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2011.10649.x","article-title":"Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"166","author":"Tohyama","year":"2012","journal-title":"Br J Dermatol"},{"key":"R90-20250602","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archderm.138.1.29","article-title":"Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples","volume":"138","author":"Correia","year":"2002","journal-title":"Arch Dermatol"},{"key":"R91-20250602","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"R92-20250602","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"R93-20250602","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J Biol Chem"},{"key":"R94-20250602","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"R95-20250602","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nm0396-317","article-title":"Fas ligand in human serum","volume":"2","author":"Tanaka","year":"1996","journal-title":"Nat Med"},{"key":"R96-20250602","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"R97-20250602","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: Soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"},{"key":"R98-20250602","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.jid.5700648","article-title":"Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas","volume":"127","author":"Stur","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R99-20250602","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"R100-20250602","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R101-20250602","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"R102-20250602","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"R103-20250602","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2133.2012.10921.x","article-title":"Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome","volume":"167","author":"Saito","year":"2012","journal-title":"Br J Dermatol"},{"key":"R104-20250602","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: Biogenesis, biologic function and clinical potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"R105-20250602","doi-asserted-by":"crossref","first-page":"eaaw6142","DOI":"10.1126\/scitranslmed.aaw6142","article-title":"Plasma exosomal miR-375-3p regulates mitochondria-dependent keratinocyte apoptosis by targeting XIAP in severe drug-induced skin reactions","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"R106-20250602","doi-asserted-by":"crossref","first-page":"245ra295","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"R107-20250602","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N Engl J Med"},{"key":"R108-20250602","doi-asserted-by":"crossref","first-page":"eaax2398","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"R109-20250602","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2012.09.014","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients","volume":"131","author":"Saito","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R110-20250602","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R111-20250602","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"R112-20250602","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2567.2001.01310.x","article-title":"Acholeplasma laidlawii up-regulates granulysin gene expression via transcription factor activator protein-1 in a human monocytic cell line, THP-1","volume":"104","author":"Kida","year":"2001","journal-title":"Immunology"},{"key":"R113-20250602","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R114-20250602","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.anai.2014.05.006","article-title":"Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: Focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10","volume":"113","author":"Wang","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R115-20250602","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-\u03b1 and CCL27 in serum and blister of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"R116-20250602","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2011.00033","article-title":"The human cutaneous chemokine system","volume":"2","author":"McCully","year":"2011","journal-title":"Front Immunol"},{"key":"R117-20250602","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","article-title":"Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions","volume":"114","author":"Tapia","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R118-20250602","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R119-20250602","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm0297-189","article-title":"Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis","volume":"3","author":"McInnes","year":"1997","journal-title":"Nat Med"},{"key":"R120-20250602","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.jaip.2019.05.002","article-title":"Galectin-7 as a potential biomarker of Stevens-Johnson syndrome\/toxic epidermal necrolysis: Identification by targeted proteomics using causative drug-exposed peripheral blood cells","volume":"7","author":"Hama","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R121-20250602","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.aca.2017.01.059","article-title":"A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition","volume":"964","author":"Vidova","year":"2017","journal-title":"Anal Chim Acta"},{"key":"R122-20250602","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jaip.2020.01.006","article-title":"RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"8","author":"Hasegawa","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R123-20250602","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.201406-1095OC","article-title":"Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation","volume":"190","author":"Qing","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R124-20250602","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: A concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"key":"R125-20250602","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"R126-20250602","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R127-20250602","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"R128-20250602","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R129-20250602","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00006454-198205000-00005","article-title":"Stevens-Johnson syndrome in children","volume":"1","author":"Ginsburg","year":"1982","journal-title":"Pediatr Infect Dis"},{"key":"R130-20250602","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"R131-20250602","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R132-20250602","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"R133-20250602","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"R134-20250602","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R135-20250602","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R136-20250602","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R137-20250602","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"R138-20250602","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R139-20250602","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R140-20250602","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"R141-20250602","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: Does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"R142-20250602","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: A retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"R143-20250602","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J Rheumatol"},{"issue":"6 Pt 1","key":"R144-20250602","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"R145-20250602","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: A retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"R146-20250602","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): Clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"key":"R147-20250602","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"R148-20250602","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"Int J Dermatol"},{"key":"R149-20250602","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R150-20250602","doi-asserted-by":"crossref","first-page":"750173","DOI":"10.3389\/fphar.2021.750173","article-title":"Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis: A propensity-matched retrospective study in China","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R151-20250602","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol"},{"key":"R152-20250602","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"R153-20250602","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R154-20250602","doi-asserted-by":"crossref","first-page":"13030\/qt3m82s074","DOI":"10.5070\/D32210032890","article-title":"Cyclosporine in toxic epidermal necrolysis: A brief review of the emerging therapeutic modality","volume":"22","author":"Kumar","year":"2016","journal-title":"Dermatol Online J"},{"key":"R155-20250602","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: Evidence from three different approaches","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R156-20250602","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R157-20250602","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jid.2017.07.828","article-title":"New evidence supporting cyclosporine efficacy in epidermal necrolysis","volume":"137","author":"Roujeau","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R158-20250602","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"R159-20250602","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","article-title":"Use of cyclosporine for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Shah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R160-20250602","doi-asserted-by":"crossref","first-page":"e12758","DOI":"10.1111\/dth.12758","article-title":"Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"32","author":"Gilbert","year":"2019","journal-title":"Dermatol Ther"},{"key":"R161-20250602","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"R162-20250602","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"R163-20250602","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"R164-20250602","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","article-title":"A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis","volume":"2","author":"Yamada","year":"1998","journal-title":"Ther Apher"},{"key":"R165-20250602","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R166-20250602","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"R167-20250602","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive Care Med"},{"key":"R168-20250602","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"R169-20250602","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: Preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"R170-20250602","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study","volume":"42","author":"Han","year":"2017","journal-title":"J Crit Care"},{"key":"R171-20250602","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"R172-20250602","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/pde.12029","article-title":"Toxic epidermal necrolysis in a child successfully treated with infliximab","volume":"31","author":"Scott-Lang","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"R173-20250602","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"R174-20250602","first-page":"61","article-title":"Toxic epidermal necrolysis successfully treated with infliximab","volume":"23","author":"Z\u00e1rate-Correa","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R175-20250602","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"key":"R176-20250602","first-page":"915314","article-title":"Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: Successful treatment of an elderly patient","volume":"2012","author":"Patmanidis","year":"2012","journal-title":"Case Rep Dermatol Med"},{"key":"R177-20250602","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"R178-20250602","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: A multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:07:53Z","timestamp":1748891273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":178,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003250","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"2024-05-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}